Testing IDP-001 for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid cancer (not blood cancer) that is advanced, has spread, or has come back, and cannot be treated with surgery or approved drugs
- Your cancer can be measured on imaging scans (RECIST v1.1 criteria)
- You are well enough to be active most of the day (ECOG performance status 0–1)
- You have adequate liver, kidney, and heart function
- You are willing to have tumor biopsies taken during the study
- You expect to live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.